Nonischemic dilated cardiomyopathy patients do not appear to benefit from additional primary prevention implantable cardioverter-defibrillator therapy in the setting of heart failure patients with cardiac resynchronization therapy indication when compared to those with ischemic cardiomyopathy, according to research published in the Journal of the American College of Cardiology, in which observational multicenter consortium data network from France, Sweden and the United Kingdom was queried. Read more >>>